Nivolumab in combination with chemotherapy for previously untreated unresectable or metastatic urothelial cancer

Nivolumab in combination with chemotherapy is in development for the treatment of patients
with previously untreated, unresectable or metastatic urothelial cancer (UC). UC occurs on the
lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system.
Metastatic UC occurs when the cancer has spread to other parts of the body. Durable responses
are rare with current standard of care treatments. Common symptoms of UC include pain or a
burning sensation when passing urine, weight loss and back/lower tummy/bone pain. Therefore,
treatment approaches with longer-term disease control and extending to broader metastatic UC
patient populations are needed.